Training Program in Lung Biology and Translational Medicine

肺生物学和转化医学培训计划

基本信息

项目摘要

 DESCRIPTION (provided by applicant): The Training Program in Lung Biology and Translational Medicine at the University of Alabama at Birmingham (UAB) provides multidisciplinary training in a stimulating and collaborative environment that nurtures the development of highly competent and innovative biomedical research scientists. This Program, initiated in 2010 to train M.D. or Ph.D. postdoctoral fellows in lung-related research, is currentl in its 4th year with a current allocation of 5 trainees (2-3-4-5-5, for years 1-5). In the first 3. years of the Program, we have graduated three trainees, all in academic research positions, two of the three are in full-time academic research faculty positions and the third receiving advanced post-doctoral training at another institution; with five additional trainees currently in the Progrm. The multidisciplinary and translational approach to the proposed training has been highly successful, and is highlighted by a diverse and interactive group of thirty faculty mentors who hold primary appointments in eight UAB Departments (4 - basic science; 4 - clinical). This includes the successful transition of "junior mentors" to the regular faculty mentoring pool. The faculty mentors are grouped into three thematic areas based on scientific expertise: (1) immunology-microbiology; (2) cell biology-tissue repair; (3) translational sciences. Translational research in statistical genetics, computational biology, biomarker discovery, and drug discovery/development and clinical trials (group 3) will facilitate the clinical translation of basc science research (groups 1 and 2). Based on the existing expertise and ongoing research efforts at UAB, training will focus on the manifestations, diagnosis, risk/prognostic stratificatio, mechanisms, prevention, and treatment of lung diseases, primarily acute lung injury (ALI), cystic fibrosis (CF), asthma, chronic obstructive lung diseases (COPD), and interstitial lung diseases (ILD). Training programs will be highly individualized and tailored to maximize success of each trainee with the creation of individual development plans (IDPs). In addition to the research projects that will be conducted in the mentor's laboratory, training will encompass a highly structured didactic program that includes weekly teaching conferences in the Division of Pulmonary, Allergy and Critical Care Medicine, a "survival skills" curriculum (in collaboration with the UAB Office of Postdoctoral Education) and a Research Core Curriculum that includes emerging themes such as cellular plasticity, drug discovery/development, "big data", computational biology, and personalized medicine. Formal instruction will include the responsible and ethical conduct of research. A priority in the next phase of this Program is the recruitment/retention of underrepresented minorities, and maintaining the current high-rate of trainee retention in academic biomedical research careers.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Victor J. Thannickal其他文献

Long noncoding RNA Malat1 regulates differential activation of macrophage and response to lung injury
长非编码 RNA Malat1 调节巨噬细胞的差异激活和对肺损伤的反应
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Huachun Cui;Sami Banerjee;Sijia Guo;Na Xie;Jing Ge;Dingyuan Jiang;Martin Zörnig;Victor J. Thannickal;Gang Liu
  • 通讯作者:
    Gang Liu

Victor J. Thannickal的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Victor J. Thannickal', 18)}}的其他基金

AMPK in the Development and Resolution of Lung Fibrosis
AMPK 在肺纤维化的发展和解决中的作用
  • 批准号:
    10320917
  • 财政年份:
    2019
  • 资助金额:
    $ 36.24万
  • 项目类别:
AMPK in the Development and Resolution of Lung Fibrosis
AMPK 在肺纤维化的发展和解决中的作用
  • 批准号:
    10083647
  • 财政年份:
    2019
  • 资助金额:
    $ 36.24万
  • 项目类别:
Sirtuins in Lung Aging and Fibrosis
Sirtuins 在肺衰老和纤维化中的作用
  • 批准号:
    10513291
  • 财政年份:
    2016
  • 资助金额:
    $ 36.24万
  • 项目类别:
Sirtuins in Lung Aging and Fibrosis
Sirtuins 在肺衰老和纤维化中的作用
  • 批准号:
    10610127
  • 财政年份:
    2016
  • 资助金额:
    $ 36.24万
  • 项目类别:
Sirtuins in Lung Aging and Fibrosis
Sirtuins 在肺衰老和纤维化中的作用
  • 批准号:
    9210543
  • 财政年份:
    2016
  • 资助金额:
    $ 36.24万
  • 项目类别:
Myofibroblast Senescence in Pulmonary Fibrosis
肺纤维化中的肌成纤维细胞衰老
  • 批准号:
    8916533
  • 财政年份:
    2014
  • 资助金额:
    $ 36.24万
  • 项目类别:
Myofibroblast Senescence in Pulmonary Fibrosis
肺纤维化中的肌成纤维细胞衰老
  • 批准号:
    8786336
  • 财政年份:
    2014
  • 资助金额:
    $ 36.24万
  • 项目类别:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
纤维化肺病中肌成纤维细胞的治疗靶向
  • 批准号:
    10218247
  • 财政年份:
    2013
  • 资助金额:
    $ 36.24万
  • 项目类别:
Administrative and Biostatistical Core
行政和生物统计核心
  • 批准号:
    10218248
  • 财政年份:
    2013
  • 资助金额:
    $ 36.24万
  • 项目类别:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
纤维化肺病中肌成纤维细胞的治疗靶向
  • 批准号:
    9980973
  • 财政年份:
    2013
  • 资助金额:
    $ 36.24万
  • 项目类别:

相似国自然基金

胚胎脑发育的分子机理:lgl2(late gestation lung 2)蛋白质的生物学功能的研究
  • 批准号:
    30470854
  • 批准年份:
    2004
  • 资助金额:
    18.0 万元
  • 项目类别:
    面上项目

相似海外基金

Interplay of the extracellular matrix and immune cells in lung pathology: key role for chitinase-like proteins
肺病理学中细胞外基质和免疫细胞的相互作用:几丁质酶样蛋白的关键作用
  • 批准号:
    MR/Y003683/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Research Grant
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
  • 批准号:
    10481965
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
Uncovering the epigenetic face of lung fibrosis for discovery of novel biomarkers and treatments.
揭示肺纤维化的表观遗传面,以发现新的生物标志物和治疗方法。
  • 批准号:
    MR/X032914/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Fellowship
Persistent micro- and nanoplastics as triggers for interstitial lung disease
持久性微塑料和纳米塑料是间质性肺病的诱因
  • 批准号:
    MR/Y012682/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Research Grant
気道上皮バリアに着目した肺NTM症Lung-on-a-chipモデルの構築と応用
关注气道上皮屏障的肺NTM疾病芯片肺模型的构建与应用
  • 批准号:
    24K19096
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
Interaction between immunity and airway remodelling in lung disease.
肺部疾病中免疫与气道重塑之间的相互作用。
  • 批准号:
    502582
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
Bioactive fragments of the extracellular matrix orchestrate lung epithelial cell repair.
细胞外基质的生物活性片段协调肺上皮细胞修复。
  • 批准号:
    BB/Y004183/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Research Grant
Tractable human distal lung organoid model as a new efficient tool to study mesenchymal-epithelial interactions in COPD
易处理的人远端肺类器官模型作为研究慢性阻塞性肺病间充质-上皮相互作用的新有效工具
  • 批准号:
    NC/Y500641/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Training Grant
Cellular dynamics in chronic lung disease: the neglected B cell axis
慢性肺病的细胞动力学:被忽视的 B 细胞轴
  • 批准号:
    MR/X03383X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.24万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了